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Balancing Long-Term Risks for Bleeding and Thrombosis*Samin K. Sharma, MD, Usman Baber, MD, MSSEE PAGE 1036W hile results from randomized trialsinitially demonstrated the superiority ofﬁrst-generation drug-eluting stents (DES)
in reducing restenosis (1), subsequent ﬁndings from
registry-based analyses alerted both lay and clinical
communities to the potential for late thrombosis
associated with these devices, particularly in the
context of “premature” dual antiplatelet therapy
(DAPT) cessation. Not surprisingly, consensus state-
ments and guidelines emerged recommending a
minimal duration of at least 12 months of DAPT
after DES implantation. Consensus surrounding the
optimal duration of DAPT soon shifted to clinical
equipoise, however, with the introduction of safer
newer-generation DES (2), along with a heightened
awareness of bleeding as a strong and independent
correlate of post-percutaneous coronary intervention
(PCI) mortality risk (3). This evolving clinical space
has been subject to at least 10 randomized trials
involving >30,000 patients (4,5). Overall, ﬁndings
from these studies have shown that prolonging
DAPT signiﬁcantly reduces coronary thrombotic
events, albeit at an excess risk of nonfatal bleeding,
with increased rates of noncardiac and all-cause mor-
tality (4,6). As a result, and in the absence of any mor-
tality beneﬁt, informing clinical decisions vis-à-vis
DAPT duration post-PCI must be predicated on
assessing long-term risks for both ischemic and hem-
orrhagic complications after PCI. Although the former
has been evaluated in multiple studies, analogous
data with respect to bleeding have primarily focused*Editorials published in the Journal of the American College of Cardiology
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relevant to the contents of this paper to disclose.on periprocedural events, a period in which the clin-
ical relevance of longer versus short DAPT duration
is much less meaningful.To address this important gap, in this issue of the
Journal, Généreux et al. (7) report their ﬁndings from
a post-hoc analysis of the ADAPT-DES (Assessment of
Dual Antiplatelet Therapy With Drug-Eluting Stents)
registry examining the incidence, determinants, and
impact of post-discharge bleeding (PDB) over 2 years
in 8,577 patients undergoing PCI with DES. PDB
included a composite of hemorrhage requiring medi-
cal attention, TIMI (Thrombolysis In Myocardial
Infarction) minor or major bleeding, ACUITY major
bleeding, or GUSTO (Global Use of Strategies to Open
Occluded Coronary Arteries) moderate or severe
bleeding. Strengths of this study include an all-
comers design, large sample size with 2-year follow-
up, generalizability to contemporary PCI practice
with predominant new-generation DES use, and an
analytic approach that accounts for the timing of
events when generating risk estimates. Key ﬁndings
indicate that PDB is not uncommon, with a 2-year
incidence of 6.6%, and is associated with a 5-fold
higher adjusted risk for mortality compared to pa-
tients without bleeding. The magnitude of incre-
mental risk with PDB also appears constant for events
occurring after 30 or 365 days. Additionally, PDB was
associated with an approximate 3-fold higher mor-
tality risk compared with post-discharge myocardial
infarction (MI).
The authors identiﬁed several unique deter-
minants of bleeding events occurring over a 2-year
period after PCI, ﬁndings that represent an impor-
tant extension of earlier work primarily focusing on
periprocedural hemorrhagic complications (8–10). In
fully adjusted analyses, older age, anemia, prior
vascular disease, low platelet reactivity, and complex






























Periprocedural Up to 1 Year Up to 3 Years
Timing of Bleeding or Thrombosis in Relation to Index Presentation or PCI
Bleeding Myocardial Infarction
Adjusted hazard ratios (95% conﬁdence intervals) for all-cause mortality associated with
either bleeding or myocardial infarction (MI) are shown for selected studies. Lines repre-
sent 95% conﬁdence intervals, and boxes adjusted point estimates. Timing of bleeding and
MI after index presentation or percutaneous coronary intervention (PCI) are shown in the
x-axis. Timing of mortality assessment varied across studies. References: Lindsey et al.
2009 (8); Mehran et al. 2009 (17); Kazi et al. 2015 (16); Stone et al. 2014 (19);
Kikkert et al. 2013 (20); Kim et al. 2011 (21); Généreux et al. 2015 (7).
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1047coronary anatomy all emerged as independent risk
factors for PDB, results that parallel established as-
sociations between these parameters and in-hospital
bleeding. By contrast, female sex and chronic kid-
ney disease, both of which are consistent and strong
correlates of early bleeding events, were absent in the
fully adjusted model for longer-term PDB. One
possible interpretation of this result: the underlying
mechanisms, and as a corollary, risk factors for
bleeding may vary over time, analogous to clinical
and procedural parameters that differentially inﬂu-
ence risk for early and late stent thrombosis (11). In
support of this rationale, female sex was not identi-
ﬁed as an independent correlate of longer-term
bleeding complications in several previous studies
(12,13). Moreover, although Généreux et al. (7) report
a strong and inverse association between platelet
reactivity and PDB, this biomarker’s physiological
relevance as a discriminator for bleeding may be
higher with earlier (14) as opposed to later events (15).
These ﬁndings also reinforce the need to reliably
estimate not just short, but also long-term risks
for both bleeding and ischemic events after PCI,
a necessary process to inform clinical decisions
regarding DAPT duration. As the authors point out,
this task is difﬁcult because risk factors for both
events tend to overlap. Nevertheless, although pre-
dicted estimates for both complications may be
similar for many patients, the degree of overlap
observed in clinical studies tends to be modest. In a
recent report from the Journal examining the impact
of bleeding or MI among patients in a large integrated
health care system (N ¼ 32,096), for example, only
39 (0.1%) experienced both events in the ﬁrst year
after PCI (16). This result implies the presence of
unique, or perhaps unknown, parameters that dif-
ferentially modify risk for either bleeding or throm-
bosis that extend beyond standard clinical and
demographic risk factors. Moreover, risk estimation
is generally performed at a singular point in time
and is therefore usually a static determination;
this limitation ignores the temporal variability and
dynamic nature of certain variables, such as medica-
tion exposure, that strongly inﬂuence risk after PCI.
Improving upon existing methods to estimate long-
term bleeding and thrombotic risk after PCI will be
needed to optimize the choice, potency, and duration
of DAPT in the current era.
Another intriguing result from the current study
is the large and signiﬁcant gradient in morality risk
related to PDB versus post-discharge MI (adjusted
hazard ratio [HR]: 5.03 vs. 1.92; p ¼ 0.008). This
ﬁnding contrasts with most (9,15–19), but not all
(8,20,21), previous reports showing a much morecomparable effect of MI and bleeding on mortality,
including 1-year results from the ADAPT-DES study
(Figure 1).
These ﬁndings are not entirely unexpected, how-
ever, when considered in the context of several
possible hypotheses. First, mortality risks after coro-
nary thrombosis may be higher with earlier as
opposed to later events, whereas risk after bleeding
appears more uniform over time. For example, al-
though acute and subacute stent thromboses are
associated with case fatality rates approaching 60%
(22), more contemporary data suggest a much lower
in-hospital mortality of approximately 4% for very
late events (23). As a result, although MI occurring
in the ﬁrst year after PCI in ADAPT-DES was associ-
ated with a 4-fold higher risk for mortality (15),
the adjusted HR of 1.92 for 2-year mortality now
reported by Généreux et al. (7) may represent a
weighted average of higher-risk earlier and lower-risk
later coronary thrombotic events. By contrast, mor-
tality risk after bleeding demonstrates less temporal
variability (3,9,18). In fact, the HR for mortality haz-
ard associated with bleeding reported at 1 year from
this cohort was 4.2, almost identical to the adjusted
point estimate of 5.0 for 2-year mortality shown in
this report.
Second, mortality risks associated with either cor-
onary thrombosis or bleeding may be strongly
Sharma and Baber J A C C V O L . 6 6 , N O . 9 , 2 0 1 5
Bleeding and Thrombosis After PCI S E P T E M B E R 1 , 2 0 1 5 : 1 0 4 6 – 9
1048inﬂuenced by prevalent DAPT usage in the population
under study. This rationale is supported by previous
observations showing that cardiac risk is higher in
acute coronary syndrome patients who are taking
versus not taking aspirin at the time of MI (“aspirin
paradox”) (24,25). By contrast, bleeding events that
occur in the setting of aspirin alone may confer a
much higher mortality risk compared with bleeds
that occur in the setting of DAPT (26). Although the
authors did not speciﬁcally address this question in
the current analysis, the potential inﬂuence of DAPT
usage as a modiﬁer of MI- and bleeding-related mor-
tality risk may be particularly relevant because >50%
of patients were no longer taking DAPT by 2 years.
Finally, changes in the epidemiology of death after
PCI indicate that a larger proportion of deaths are
now due to noncardiac rather than cardiac causes
(27). In part, these trends may reﬂect selection of
patients with more comorbid conditions, including
malignancy, to undergo PCI in the contemporary era.
As a result, the negative impact of bleeding may
outweigh risk from coronary thrombosis. Indeed, the
proportion of cardiac deaths in the current study was
much lower among patients with versus without
bleeding (36.8% vs. 59.3%).
The current ﬁndings by Généreux et al. (7) add novel
and clinically relevant insight that will continue to
inform the evolving paradigm of DAPT after PCI.
Although the focus approximately 10 years ago wasclearly towards longer DAPT durations for most pa-
tients, the pendulum has now shifted towards a more
nuanced and individualized approach that in-
corporates risks for both bleeding and thrombosis.
Within this context, the identiﬁcation of risk factors
for late bleeding after PCI is an important ﬁrst step
towards developing and validating risk models that
may identify patients most likely (or unlikely) to
realize any beneﬁt from a longer DAPT duration. In
addition to development, such tools require imple-
mentation to improve existing processes of care.
Although electronic integration of bleeding risk esti-
mates as part of pre-procedural risk stratiﬁcation led to
more rational use of bleeding avoidance strategies and
lowered in-hospital bleeding complications (28,29),
further evaluation is now required for longer-term
pharmacotherapy and bleeding risk. Alternatively,
the emerging relevance of later bleeding after PCI re-
inforces the need to identify novel approaches towards
long-term pharmacotherapy in such patients, such as
aspirin withdrawal. In concert, these methods will
allow us to achieve more efﬁcient, safer, and ulti-
mately, better care for our patients after PCI (30).
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